Skip to content
Press Releases
Filter Releases
 
Press Releases
Dec 16, 2013
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2013 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced that Cigna, one of the nation's leading providers of health insurance, has issued a positive coverage policy for the company's Afirma Gene Expression Classifier (GEC). ...
PDF
Nov 25, 2013
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2013 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) today reported financial results for the third quarter ended September 30, 2013, and provided an update on recent business progress. Revenue was $5.6 million for the third quarter of 2013, versus $3.2 million for the third quarter of 2012, an increase of 74%. R...
PDF
Nov 13, 2013
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2013 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) today announced that it presented new data suggesting the ability of its Afirma Gene Expression Classifier (GEC) to accurately identify medullary thyroid cancer (MTC) among thyroid nodule fine needle aspiration (FNA) samples that are indeterminate and sub-class...
PDF
Nov 11, 2013
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2013 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) announced today that its third quarter 2013 financial results will be released after close of market on Monday, November 25, 2013.  Following the release, Veracyte will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the company's f...
PDF
Nov 4, 2013
SOUTH SAN FRANCISCO, Calif., Nov. 4, 2013 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) announced today the closing of its initial public offering of 5,000,000 shares of its common stock resulting in net proceeds of approximately $58.0 million after deducting underwriting discounts and commissions and estimated expenses.  All of the shares of commo...
PDF
Oct 30, 2013
SOUTH SAN FRANCISCO, Calif. - October 30, 2013 - Veracyte, Inc. announced today the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $13.00 per share.   All of the shares of common stock are being offered by Veracyte.  Veracyte has granted the underwriters a 30-day optio...
PDF
Oct 23, 2013
South San Francisco, Calif. --- October 23, 2013 --- Data from a new long-term, multicenter study confirm the accuracy of the Afirma Gene Expression Classifier (GEC) in identifying benign thyroid nodule fine needle aspiration (FNA) biopsies among those initially deemed indeterminate, or inconclusive, by cytopathology, Veracyte, Inc. announced today...
PDF
Oct 18, 2013
South San Francisco, Calif. --- October 18, 2013 --- Veracyte, Inc., a molecular diagnostics company pioneering the field of molecular cytology, today announced preliminary study results suggesting the potential for an RNA-based gene expression test to accurately detect the BRAF V600E gene mutation in thyroid nodule fine needle aspiration (FNA) sam...
PDF
Sep 20, 2013
South San Francisco, Calif. – September 20, 2013 - Veracyte, Inc. today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed initial public offering of its common stock. All of the shares to be sold in the proposed offering will be offered by Veracyte, Inc. The numb...
PDF
Jul 8, 2013
South San Francisco, Calif. --- July 8, 2013 --- Veracyte, Inc., a molecular diagnostics company pioneering the field of molecular cytology, today announced that Aetna, the third largest health plan in the United States, has issued a positive coverage policy for the company’s Afirma Gene Expression Cl...
PDF
Page: First Previous
...
Next Last